Indian generics wave next year set to sink obesity drug price

Leading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, potentially up to 80%. This will make the drug more accessible to obese and diabetes patients. The domestic weight-loss drug market is expected to grow substantially. Semaglutide patent expiry will trigger price erosion and increased adoption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0384zN
via IFTTT

Read More

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims for a significant market share. Several Indian drugmakers are also preparing to launch generic versions. Eris has experience with diabetes drugs. The company hopes to leverage its existing portfolio. It includes orals, insulin, and GLP-1.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0wQPGY2
via IFTTT

Read More

Pharma tariffs may go as high as 250%, says Trump

U.S. President Donald Trump said new tariffs on imported pharmaceuticals will start small but could rise to 250% within 18 months to boost domestic production. He also plans to announce fresh duties on foreign semiconductors, aiming to reduce U.S. reliance on overseas supply chains.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xS1FQAT
via IFTTT

Read More

Mind, muscle, and metabolism: The power of holistic diabetes management

Managing diabetes holistically involves more than just blood sugar control, encompassing lifestyle factors like diet, exercise, and mental well-being. Small changes, such as increasing fiber intake and regular walking, can significantly impact health. Understanding hormones like GLP-1 and insulin, along with addressing stress and sleep, are crucial for comprehensive diabetes care and improved overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/THnDtI9
via IFTTT

Read More

Corner Office Conversation with The New Leaders of Indian Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yagzUpd
via IFTTT

Read More

Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr

Manipal Hospitals is planning to acquire Sahyadri Hospitals. The deal is estimated at around Rs 6,400 crore. Manipal has sought approval from the Competition Commission of India. This acquisition will significantly expand Manipal's presence in western India. It will also increase Manipal's total bed count to approximately 12,000. Sahyadri Hospitals currently operates 11 hospitals in Maharashtra.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Iv06Knp
via IFTTT

Read More

70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the multi-center study across 20 Indian sites. The budget is approximately Rs 1.3 to 1.5 crore per site. Dengue cases are rising, with over 5 lakh confirmed in 2024. The government monitors outbreaks and provides support to states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYMrA1o
via IFTTT

Read More